(Q37947902)

25 August 2017

title

Beyond trastuzumab: new treatment options for HER2-positive breast cancer (English)

1 reference

25 August 2017

1 reference

6

Evandro de Azambuja

0 references

Sherene Loi

object named as

Sherene Loi

4

0 references

author name string

Kamal S Saini

1

1 reference

25 August 2017

Hatem A Azim

2

1 reference

25 August 2017

Otto Metzger-Filho

3

1 reference

25 August 2017

Christos Sotiriou

5

1 reference

25 August 2017

Martine Piccart

7

1 reference

25 August 2017

publication date

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

20 Suppl 3

1 reference

25 August 2017

page(s)

S20-7

1 reference

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Expression of cellular oncogenes in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

The PIK3CA gene is mutated with high frequency in human breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

The role of mitogen-activated protein (MAP) kinase in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Simultaneous targeting of estrogen receptor and HER2 in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Targeting Her-2/neu in breast cancer: as easy as this!

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

The multiple roles of PTEN in tumor suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

erbB2 is required for G protein-coupled receptor signaling in the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Essential roles of Her2/erbB2 in cardiac development and function

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Requirement for neuregulin receptor erbB2 in neural and cardiac development

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Resistance to Trastuzumab in Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Trastuzumab versus lapatinib: the cardiac side of the story

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Lapatinib-associated toxicity and practical management recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Jumping higher: is it still possible? The ALTTO trial challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Whither HER2-related therapeutics?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

Trastuzumab in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2811%2970289-2

7 January 2021

10.1016/S0960-9776(11)70289-2

Identifiers

DOI

1 reference

25 August 2017

1 reference